Clinical Trial Update: Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating trametinib plus hydroxychloroquine in KRAS-mutant biliary tract cancers was terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bile Duct Cancer
• Biliary Cancer
• Biliary Tract Neoplasms
• Cholangiocarcinoma

Drugs mentioned

• Hydroxychloroquine (hydroxychloroquine)
• Trametinib (trametinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Bile Duct Cancer, Biliary Cancer | Phase 2 | Status: TERMINATED | Results posted: 2023-08-21